Abliva Company Profile: Stock Performance & Earnings

Abliva Overview

Founded
2000

Status
Public

Employees
9

Stock Symbol
ABLI

Investments
2

Share Price
$0.11
(As of Thursday Closing)

Abliva General Information

Description

Abliva AB is a Swedish company which is active in pharmaceutical development. Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Contact Information

Website

www.abliva.com

Formerly Known As

NeuroVive Pharmaceutical AB, NeuroVive Pharmaceutical

Ownership Status

Publicly Held

Financing Status

Formerly VC-backed

Primary Industry

Pharmaceuticals

Stock Exchange

STO

Primary Office

Medicon Village
223 81 Lund
Sweden

+46 046-275 00 00



Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abliva Stock Performance

(As of Thursday Closing)

Stock Price	Previous Close	52 wk Range	Market Cap	Shares	Average Volume	EPS
$0.11	$0.11	$0.05 - $0.28	$32.4M	296M	12.7M	-$0.05

Abliva Financials Summary

In Thousands, USD	TTM 30-Jun-2020	FY 2019 31-Dec-2019	FY 2018 31-Dec-2018	FY 2017 31-Dec-2017
EV	26,148	18,505	10,367	14,513
Revenue	16	14	1	3
EBITDA	(7,958)	(7,889)	(8,157)	(8,175)
Net Income	(8,215)	(8,140)	(7,858)	(7,807)
Total Assets	17,187	15,882	12,828	14,671
Total Debt	0	0	0	0

Public Fundamental Data provided by Morningstar, Inc. disclaimer

Abliva Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Abliva‘s full profile, request access.

Request a free trial

Abliva Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Abliva AB is a Swedish company which is active in pharmaceutical development. Abliva develops medicines for the treatmen

Pharmaceuticals

Lund, Sweden

9 As of 2020

000.00

000000000 000.00

00000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c

000000000000000

Uppsala, Sweden

000 As of 0000

000.00

0000 0000-00-00

00000000 000.00

00000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l

000000000000000

Durham, NC

00 As of 0000

00000

000000 - 000 00000

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Abliva Competitors (36)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Date/Type	Last Financing Amount
Orexo	Formerly VC-backed	Uppsala, Sweden	000	000.00	00000000	000.00
00000000	Formerly VC-backed	Durham, NC	00	00000	000000 - 000	00000
000000 00000000000	Formerly VC-backed	San Diego, CA	000	00000	000000&0
00000000	Formerly VC-backed	Durham, NC	00	00000	000000000	00000
00000000	Corporation	Richmond, VA	000	00000	0000	00000

You’re viewing 5 of 36 competitors. Get the full list »

Abliva Executive Team (7)

Name	Title	Board Seat	Contact Info
Erik Kinnman Ph.D	Chief Executive Officer
Catharina Johansson	Chief Financial Officer & Vice President, Investor Relations & Communications
Magnus Hansson	Chief Medical Officer & Vice President, Preclinical and Clinical Development
Eskil Elmér	Vice President Discovery & Chief Scientific Officer